USSN: 09/736,858 Ref. No. 030116 (formerly 6295.N)

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula I

$$R_2$$
 $B \longrightarrow A-CH_2-W$

T

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii,

B is

(a)
$$\begin{array}{c} R_4 & (CH_2)_{R} \\ \hline & (CH_2)_{i} \end{array} Z$$

(b)
$$-N$$
 $(CH_2)_n$, or

W is NHC(=X)R₁, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is $S(=0)(=N-R_5)$;

Ref. No. 030116 (formerly 6295.N)

 R_1 is

- (a) H,
- (b) NH_2 ,
- (c) NHC₁₋₄alkyl,
- (d) C_{1-4} alkyl,
- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) $(CH_2)_p C_{3-6}$ cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) $C(=O)C_{1-4}alkyl$,
- (d) $C(=O)OC_{1-4}alkyl$,
- (e) $C(=O)NHR_6$, or
- (f) $C(=S)NHR_{6}$

 R_6 is H, C_{1-4} alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C_{1.4}alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mR₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; when R₅ is C₁₋₄alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;

Ref. No. 030116 (formerly 6295.N)

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5; m is 0, 1, or 2; and n is 2 or 3.

2. (Previously Presented) A compound of claim 1 having the formula IA:

$$\begin{array}{c} R_2 \\ R_3 \end{array} \longrightarrow \begin{array}{c} O \\ N \\ H \end{array} X \\ R_1 \end{array}$$

IA.

- 3. (Original) A compound of claim 2 wherein R₁ is C₁₋₄alkyl.
- 4. (Original) A compound of claim 2 wherein R_1 is ethyl.
- 5. (Original) A compound of claim 2 wherein R_1 is methyl.
- 6. (Original) A compound of claim 2 wherein R_1 is C_{3-6} cycloalkyl.
- 7. (Original) A compound of claim 2 wherein R₁ is cyclopropyl.
- 8. (Previously Presented) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X is a sulfur atom.
- 9. (Previously Presented) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X is an oxygen atom.
- 10. (Original) A compound of claim 8 wherein one of R_2 and R_3 is H, the other one is F.

- 11. (Original) A compound of claim 9 wherein one of R_2 and R_3 is H, the other one is F.
- 12. (Original) A compound of claim 8 wherein R₄ is H.
- 13. (Original) A compound of claim 9 wherein R₄ is H.
- 14. (Original) A compound of claim 8 wherein structure B is

wherein Z is $S(=O)(=NR_5)$.

- 15. (Canceled).
- 16. (previously amended) A compound of claim 8 wherein structure B is

$$-\langle ^{(CH_2)_p} \rangle z$$

wherein Z is $S(=O)(=NR_5)$.

17. (Original) A compound of claim 9 wherein structure B is

$$(CH_2)_p$$
 z

wherein Z is $S(=O)(=NR_5)$.

18-21, (Canceled).

22. (Original) A compound of claim 14 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁.

4alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Ref. No. 030116 (formerly 6295.N)

- 23. (Original) A compound of claim 22 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.
- 24. (Original) A compound of claim 14 wherein R_5 is $C(=0)CH_3$.
- 25. (Original) A compound of claim 14 wherein R₅ is C(=O)OCH₃.
- 26-29. (Canceled).
- 30. (Original) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.
- 31. (Original) The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.
- 32. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.
- 33. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.
- 34. (Original) A method for treating microbial infections of claim 30 wherein the infection is skin infection.
- 35. (Original) A method for treating microbial infections of claim 30 wherein the infection is eye infection.

Ref. No. 030116 (formerly 6295.N)

- 36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 37. (Canceled).
- 38. (Original) A compound of claim 16 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.
- 39. (Original) A compound of claim 38 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.
- 40. (Original) A compound of claim 16 wherein R₅ is C(=0)CH₃.
- 41. (Original) A compound of claim 16 wherein R₅ is C(=0)OCH₃.
- 42. (Original) A compound of claim 17 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.
- 43. (Original) A compound of claim 42 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.
- 44. (Original) A compound of claim 17 wherein R₅ is C(=O)CH₃.
- 45. (Original) A compound of claim 17 wherein R₅ is C(=O)OCH₃.
- 46. (Currently Amended) A compound of claim 2 which is N-[((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide; or N-[((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide-;.

USSN: 09/736,858 Ref. No. 030116 (formerly 6295.N)

47. (Previously Presented) A compound of formula II

$$R_2$$
 A -CH₂-W

П

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii

B is

$$CH_2)_p$$
 Z

W is NHC(=X) R_1 , or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is $S(=0)(=N-R_5)$ and the B ring has the following stereochemistry

 R_1 is

(a) H,

Ref. No. 030116 (formerly 6295.N)

- (b) NH_2 ,
- (c) NHC₁₋₄alkyl,
- (d) C_{1-4} alkyl,
- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) (CH₂)_p C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

 R_4 is H, CH₃, or F;

R₅ is

- (a) H,
- (b) C₁₋₄alkyl,
- (c) $C(=O)C_{1-4}alkyl$,
- (d) $C(=O)OC_{1-4}alkyl$,
- (e) $C(=O)NHR_6$, or
- (f) $C(=S)NHR_{6}$:

R₆ is H, C₁, alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; when R₅ is C₁₋₄alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;

Ref. No. 030116 (formerly 6295.N)

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5; m is 0, 1, or 2.

- 48. (Previously Presented) The compound of claim 47 wherein R₁ is C₁₋₄alkyl.
- 49. (Previously Presented) The compound of claim 47 wherein R₁ is ethyl.
- 50. (Previously Presented) The compound of claim 47 wherein R₁ is methyl.
- 51. (Previously Presented) The compound of claim 47 wherein R₁ is C₃₋₆cycloalkyl.
- 52. (Previously Presented) The compound of claim 47 wherein R₁ is cyclopropyl.
- 53. (Previously Presented). The compound of claim 47 wherein X is a sulfur atom.
- 54. (Previously Presented) The compound of claim 47 wherein X is an oxygen atom.
- 55. (Previously Presented) The compound of claim 53 wherein one of R_2 and R_3 is H, the other one is F.
- 56. (Previously Presented) The compound of claim 54 wherein one of R_2 and R_3 is H, the other one is F.
- 57. (Previously Presented) The compound of claim 47 wherein R_5 is H.
- 58. (Previously Presented) The compound of claim 47 wherein R₅ is C₁₄alkyl, optionally substituted with OH; or C₁₄alkyl substituted with C(=0)NHC₁₄alkyl,

Ref. No. 030116 (formerly 6295.N)

C(=O)NH₂ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, NO₂, CF₂, or CN.

- 59. (Previously Presented) The compound of claim 47 wherein R₅ is CH₃, or ethyl.
- 60. (Previously Presented) The compound of claim 47 wherein R₅ is C_{1.4}alkyl substituted with phenyl wherein the phenyl is optionally substituted with NO₂.
- 61. (Previously Presented) The compound of claim 47 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.
- 62. (Previously Presented) The compound of claim 47 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.
- 63. (Previously Presented) The compound of claim 47 wherein R₅ is C(=0)CH₃.
- 64. (Previously Presented) The compound of claim 47 wherein R₅ is C(=0)OCH₃.
- (Previously Presented) A compound of claim 47 which is
 N-({(5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;
 N-({(5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;
 N-({(5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide (Z)-isomer;
 N-({(5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;
 N-({(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl

yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer;

USSN: 09/736,858 Ref. No. 030116 (formerly 6295.N)

N-($\{(5S)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl]-2-oxo-1,3-oxazolidin-5-yl $\}$ methyl $\}$ propanethioamide, Z-isomer;

N-($\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl\}$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]\}$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]\}$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]\}$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]\}$ phenyl $\{(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]\}$

N-($\{(5S)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-($\{(5S)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1- $\{[(methylamino)carbonyl]imino\}$ -1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1- $\{[[(4-nitrophenyl)amino]carbonyl]imino\}$ -1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

١.

Ref. No. 030116 (formerly 6295.N)

N-($\{(5S)$ -3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanecarbothioamide, Z-isomer;

N-[((5S)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide, Z-isomer;

N-[((5S)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, Z-isomer; or

N- $({(5S)-3-[3-fluoro-4-(1-{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer.

- 66. (Previously Presented) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula II as shown in claim 47.
- 67. (Previously Presented) A compound selected from the group consisting of N-($\{(5S)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-<math>1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer, N-($\{(5S)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-<math>1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-

Ref. No. 030116 (formerly 6295.N)

isomer.